New approaches to the medical treatment of irritable bowel syndrome.

Irritable bowel syndrome (IBS) is a common disorder with a worldwide distribution; it is characterized by abdominal pain and discomfort associated with an alteration of bowel function. The treatment approach for IBS depends on the patient's presenting symptoms at the time of diagnosis, and treatment is usually directed toward the predominant symptom. In this review we discuss the current approach to the treatment of IBS.

Novel therapies in the treatment of irritable bowel syndrome.

Irritable bowel syndrome (IBS) is characterised by abnormalities in motility, sensation and perception. It is one of the most common conditions encountered in clinical practice, especially by gastroenterologists. Pharmacological treatment of IBS is aimed at the predominant symptom and recent advances in pathophysiology has opened the door to the development of new compounds that target specific receptors. During this review, the most promising investigational and recently approved drugs will be discussed.

Clinical assessment of irritable bowel syndrome.

Because irritable bowel syndrome (IBS) is a prevalent cause of visits to the gastroenterologist, it is extremely important to have accurate guidelines for the diagnosis. During the clinical assessment of IBS, the physician must look for the gastrointestinal symptoms, extraintestinal symptoms, and psychological history that are commonly associated with IBS. There are three diagnostic criteria that may be used in the IBS diagnosis: Manning, Rome I, and Rome II. Although there is discrepancy about which is most effective, we recommend that the Rome II be used in clinical practice. To confidently diagnose IBS, the physician must rule out organic disease as a cause of symptoms. This can be done by evaluating the patient's symptoms and screening for "red flags." The diagnostic strategy for IBS involves a thorough evaluation of the patient: taking a patient history, performing a physical exam, and performing the appropriate diagnostic tests when necessary.

A novel endoscopic full-thickness plicator for treatment of GERD: an animal model study.

BACKGROUND: This study was designed to demonstrate the efficacy and safety of a novel endoscopic full-thickness plication device for the treatment of GERD. METHODS: Gastric pressures and reflux from the gastroesophageal junction were measured in 20 excised pig stomachs before and after full-thickness plication within 1 cm of the gastroesophageal junction. Endoscopic full-thickness plication was performed on 11 live mini-swine that were subsequently observed for up to 12 weeks. OBSERVATIONS: Full-thickness plication significantly increased the mean intragastric pressure at which gastroesophageal reflux occurred. No complication, death, or sign of infection or tissue damage was noted by endoscopic observation or inspection of excised tissue at up to 12 weeks' follow-up. CONCLUSIONS: These studies in the ex vivo porcine model and live pigs suggest that full-thickness plication is effective and safe.

Irritable bowel syndrome patients show altered sensitivity to exogenous opioids.

Alterations in activation of pain modulation systems may play a role in the pathophysiology of irritable bowel syndrome (IBS). However, little is known about the effects of exogenous opioids on the perceptual and autonomic responses to aversive visceral stimulation. The aim of the study was to evaluate the effect of the mu opioid-preferring analgesic fentanyl (FEN), given intravenously, on perceptual and autonomic responses to rectal distension. Ten IBS patients and ten normal subjects received, on separate days, either high dose (HD) fentanyl (112 microg bolus followed by 0.04 microg/kg per min infusion), low dose (LD) fentanyl (56 microg bolus followed by 0.02 microg/kg per min) or normal saline (SAL) (50 cc bolus followed by 45 cc/h infusion). Perception thresholds for discomfort and pain during rectal distension were assessed using a tracking paradigm. Intensity and unpleasantness ratings of the distensions, and cardiac autonomic parameters were assessed during randomly delivered rectal stimuli. Effects of FEN on rectal compliance and tone as well as mental status were also assessed. IBS patients had lower perceptual thresholds for discomfort and pain under control conditions. FEN dose-dependently increased the perception thresholds in both healthy control subjects and in IBS patients with a greater relative efficacy in IBS patients than in normal subjects. IBS patients used significantly higher unpleasantness ratings of rectal stimuli compared to healthy controls, but showed no difference in the sensory intensity rating of the stimulus. FEN decreased both intensity and unpleasantness ratings for IBS and normals. FEN lowered cardiosympathetic tone in normal subjects but had no effect on IBS patients. FEN had no effect on rectal tone or compliance. FEN dose-dependently attenuates the perception of phasic rectal distension and affects unpleasantness ratings during random fixed rectal distension, with a greater relative efficacy for this antinociceptive effect in IBS patients. These findings support the hypothesis that IBS patients may have an altered central release of endogenous opioids in response to visceral stimulation.